Indivior (NASDAQ:INDV) Director Stuart Kingsley Buys 940 Shares

Indivior PLC (NASDAQ:INDV) Director Stuart Kingsley acquired 940 shares of the stock in a transaction dated Friday, March 6th. The shares were bought at an average cost of $31.86 per share, with a total value of $29,948.40. Following the completion of the purchase, the director directly owned 5,582 shares in the company, valued at approximately $177,842.52. This trade represents a 20.25% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Indivior Stock Down 7.1%

Shares of INDV stock traded down $2.35 on Thursday, reaching $30.48. 1,964,837 shares of the stock were exchanged, compared to its average volume of 1,976,938. The stock has a market cap of $3.81 billion, a P/E ratio of 18.53 and a beta of 0.83. The firm has a 50 day moving average of $33.93 and a two-hundred day moving average of $30.53. Indivior PLC has a 1-year low of $8.64 and a 1-year high of $38.00.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, February 26th. The company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.17. The firm had revenue of $358.00 million for the quarter, compared to analysts’ expectations of $305.62 million. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%. On average, equities research analysts predict that Indivior PLC will post 1.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on INDV. Weiss Ratings raised shares of Indivior from a “hold (c)” rating to a “buy (b-)” rating in a research report on Monday, March 2nd. Northland Securities set a $50.00 price objective on Indivior in a research note on Tuesday, January 20th. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Morgan Stanley reiterated an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research note on Wednesday, December 3rd. Finally, HC Wainwright boosted their price target on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Indivior currently has a consensus rating of “Moderate Buy” and an average target price of $39.33.

Hedge Funds Weigh In On Indivior

Several institutional investors and hedge funds have recently made changes to their positions in the business. CWM LLC bought a new stake in shares of Indivior in the third quarter worth $25,000. Quarry LP acquired a new position in Indivior during the 3rd quarter worth $26,000. Raymond James Financial Inc. bought a new stake in shares of Indivior in the 2nd quarter worth about $26,000. Salomon & Ludwin LLC bought a new stake in shares of Indivior in the 4th quarter worth about $30,000. Finally, Harbor Capital Advisors Inc. raised its stake in shares of Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after purchasing an additional 781 shares in the last quarter. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.